Streptococcus Pneumoniae Polysaccharide Conjugated To Corynebacterium Diphtheriae Crm197

Streptococcus pneumoniae polysaccharide conjugated to Corynebacterium diphtheriae CRM197 is a vaccine component in which pneumococcal capsular polysaccharides are covalently linked to the non-toxic CRM197 diphtheria toxin mutant carrier protein to enhance immunogenicity and provide T-cell-dependent immune responses including immunological memory in infants. The carrier protein converts the T-independent polysaccharide antigens to T-dependent antigens, enabling robust long-term protection against pneumococcal disease. This conjugation chemistry is used in the Prevnar series of pneumococcal conjugate vaccines.

Yes, Streptococcus Pneumoniae Polysaccharide Conjugated To Corynebacterium Diphtheriae Crm197 is an approved drug. It has reached clinical phase 4. It is classified as a Vaccine component.